Login to Your Account



ViroPharma Girds for Battle

FDA's Vancocin Rule-Bend: Generic Floodgate's Future?

By Randy Osborne


Monday, July 27, 2009
As the last line of defense against killer bugs, ViroPharma Inc.'s generics-threatened Vancocin (vancomycin) is "particularly ill-suited to being the test case" for an FDA plan to change the standards for bioequivalence testing of nonsystemically absorbed drugs. So wrote Michel de Rosen, CEO of ViroPharma, in a letter to the agency. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription